Uric Acid Lowering Trial in Youth Onset T2D
Фаза 2
Завершено
NCT03899883
| Заболевание | Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2 |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | University of Colorado, Denver |
|---|
| Статус | Завершено |
|---|
| Участники | 11 участн. |
|---|
| Вмешательство | Pegloticase 8 MG/ML [Krystexxa] |
|---|
| Дата начала | 1.01.2020 |
|---|
| Дата завершения | 13.04.2023 |
|---|
| Публикация результатов | 28.07.2026 |
|---|
Кратко
Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D). In fact, 50% of males with youth-onset T2D have serum uric acid (SUA) greater than 6.8 mg/dl. The investigators also recently demonstrated that higher SUA conferred greater odds of developing hypertension and diabetic kidney disease (DKD) in youth with T2D over 7 years follow-up. Elevated SUA is thought to lead to cardiovascular disease (CVD) and DKD by inflammation, mitochondrial dysfunction and deleterious effects on nephron mass. While there are studies demonstrating beneficial effects of uric acid (UA) lowering on vascular health in the general population, there are no studies in youth-onset T2D. Youth-onset T2D carries a greater risk of DKD and CVD compared to adult-onset T2D and T1D. Accordingly, a clinical trial evaluating UA lowering therapies is needed in youth-onset T2D. Krystexxa (pegloticase), a uricase, effectively lowers SUA and therefore holds promise as a novel therapy to impede the development of CVD and DKD in youth-onset T2D. This proposal describes a pilot and feasibility trial ev
Systolic Blood Pressure
Baseline and 1 week post treatment · mmHg
| Men With Youth-onset T2D | 80 ± 12 mmHg |
|---|
| Men With Youth-onset T2D | 85 ± 11 mmHg |
|---|
Diastolic Blood Pressure
Baseline and 1 week post treatment · mmHg
| Men With Youth-onset T2D | 135 ± 13 mmHg |
|---|
| Men With Youth-onset T2D | 132 ± 9 mmHg |
|---|
Mean Arterial Pressure
Baseline and 1 week post treatment · mmHg
| Men With Youth-onset T2D | 98 ± 10 mmHg |
|---|
| Men With Youth-onset T2D | 101 ± 10 mmHg |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.